$XRAY

DENTSPLY SIRONA Inc.

DENTSPLY SIRONA develops, manufactures, and markets dental products and technologies for dental professionals, as well as healthcare consumables for urinary and bowel management. Headquartered in Charlotte, North Carolina, it sells products through foreign subsidiaries to customers in approximately 140 countries. The company operates four segments: Connected Technology Solutions, which includes dental equipment, instruments, CAD/CAM products, and the DS Core cloud platform; Essential Dental Solutions, which includes endodontic, restorative, preventive, and small equipment products; Orthodontic and Implant Solutions, which includes SureSmile clear aligners, digital orthodontic services, implants, prosthetics, and digital dentures; and Wellspect Healthcare, which offers catheters and irrigation systems. DENTSPLY SIRONA sells dental products through third-party distributors and, for certain products, directly to laboratories or dental professionals. Its continence care products are sold primarily through medical-supply distributors, with some direct sales to patients and medical providers.

AlphAI earnings readQ3 FY2026 · NOV 5Dentsply Sirona Reports Third Quarter 2026 ResultsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
1

No SEC Form 4 filings for $XRAY in the last 30 days.

See all $XRAY insider activity →

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

XRAY sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning XRAY (DENTSPLY SIRONA Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent XRAY coverage spans earnings, financial news and market movers.

What's driving XRAY

AlphAI scores every news story that mentions XRAY with an AI model for sentiment and relevance, and aggregates insider trades from DENTSPLY SIRONA Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $XRAY

Score

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

$XRAYHighAI 8/10Earnings

Dentsply Sirona Reports Third Quarter 2026 Results

DENTSPLY SIRONA Inc. (XRAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Dentsply Sirona Reports Third Quarter 2026 Results News Summary • Q3 2026 net sales of $836 million • Q3 2026 GAAP gross margin of 52.9%, GAAP diluted loss per share of ($0.01) • Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, adjusted EPS of $0.29 • Achi

Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona shares are soaring, what you need to know

Shares of Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona surged after Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing. Analysts expect the biopharmaceutical sector to strengthen. Stryker (SYK) rose 8.8%, Omnicell (OMCL) 10.8%, Zimmer Biomet (ZBH) 15.2%, Artivion (AORT) 9.1%, and Dentsply Sirona (XRAY) 9.2%. Zimmer Biomet's shares hit a 52-week high of $111.96.

Related tickers